18 pages matching Tufts CSDD in this book
Results 1-3 of 18
What people are saying - Write a review
We haven't found any reviews in the usual places.
RD Spending at Top 50 Pharmaceutical Companies in 2007
50 other sections not shown
active Amgen analysis annual applications approval phase approved drug assessment AstraZeneca average billion biological products biopharmaceutical biotech biotechnology BLAs Bristol-Myers Squibb cancer Cardiovascular CBER CDER CenterWatch clinical development clinical phase clinical research clinical studies clinical trials compounds CRO usage cycle database DiMasi disease Division Drug Development drugs approved EMEA estimates Europe EvaluatePharma Fast Track FDA approval FDA's firms focus Genentech GlaxoSmithKline global Goldman Sachs increase INDs innovation investment late-stage launch Lehman Brothers Lilly median Merck months NCEs NME approvals Novartis Novo Nordisk oncology orphan drugs patient recruitment percent period Pfizer Pharma pharmaceutical companies pharmaceutical industry Pharmaprojects Phase Phase preclinical priority products approved programs projects protocol R&D pipeline R&D productivity R&D spending regulatory Roche Sanofi-Aventis Schering-Plough Source sponsors strategy Study of Drug submission Success Rates Costs/Complexity therapeutic areas Therapeutic Category therapy trial enrollments Tufts Center Tufts CSDD vaccines Wyeth